L R Zacharski
Affiliation: Dartmouth Medical School
- The statin-iron nexus: anti-inflammatory intervention for arterial disease preventionLeo R Zacharski
Research Service, Veterans Affairs Hospital, White River Junction, VT 05009, USA
Am J Public Health 103:e105-12. 2013..We postulated the existence of a statin-iron nexus by which statins improve cardiovascular disease outcomes at least partially by countering proinflammatory effects of excess iron stores...
- Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathyLeo R Zacharski
Research Service 151, VA Medical Center, White River Junction, VT 05009, USA
Cancer Lett 186:1-9. 2002....
- Atherosclerosis: a manifestation of chronic iron toxicity?Leo R Zacharski
Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
Vasc Med 8:153-5. 2003
- Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinomaLeo R Zacharski
Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, VA Medical Center, 215 North Main Street, White River Junction, Vermont 05009, USA
Expert Rev Cardiovasc Ther 2:777-84. 2004..These data suggest that drugs that are well-known in the field of vascular medicine may find a role in the treatment of hepatocellular carcinoma, a common tumor type that has resisted containment by other means...
- Implementation of an iron reduction protocol in patients with peripheral vascular disease: VA cooperative study no. 410: the Iron (Fe) and Atherosclerosis Study (FeAST)Leo R Zacharski
Department of Veterans Affairs Medical Centers, White River Junction, VT 05001, USA
Am Heart J 148:386-92. 2004....
- Warfarin versus low-molecular-weight heparin therapy in cancer patientsLeo R Zacharski
VA Medical and Regional Office Center, 215 North Main Street, White River Junction, Vermont 05009, USA
Oncologist 10:72-9. 2005..Further evaluation of the LMWHs for effects on cancer outcome is indicated...
- Hypercoagulability preceding cancer. The iron hypothesisL R Zacharski
VA Hospital, White River Junction, VT, USA
J Thromb Haemost 3:585-8. 2005
- Commentary on "The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis"Leo R Zacharski
Department of Medicine, Dartmouth Medical School, Lebanon, NH 03756, USA
Free Radic Biol Med 40:1700-1. 2006
- Venous thromboembolism prevention in cancer patients: the search for common antecedentsLeo R Zacharski
Dartmouth Hitchcock Medical Center, Department of Medicine, Section of Hematology Oncology, Lebanon, NH 03756, USA
Expert Opin Pharmacother 8:2117-25. 2007..Increasing understanding of the interplay between the coagulation mechanism and neoplasia has yielded clues to the upstream origins of both, which may lead to experimental intervention potentially capable of preventing both...
- The heparins and cancerLeo R Zacharski
The Department of Veterans Affairs Medical Center, White River Jct, Vermont 05009, USA
Curr Opin Pulm Med 8:379-82. 2002..HLGAGs may be a fundamental intermediate in the abnormal growth regulation characteristic of neoplasia that is susceptible to targeted intervention...
- Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, ItalyLeo R Zacharski
Vermont and Dartmouth Medical School, HB 7900, Lebanon, NH 03755, USA
IDrugs 6:1036-8. 2003
- The iron (Fe) and atherosclerosis study (FeAST): a pilot study of reduction of body iron stores in atherosclerotic peripheral vascular diseaseL R Zacharski
Department of Veterans Association Medical Centers, White River Junction, VT 05009 0001, USA
Am Heart J 139:337-45. 2000....
- Low-molecular-weight heparin and cancerL R Zacharski
VA Medical and Regional Office Center, White River Junction, Vermont 05009, USA
Semin Thromb Hemost 26:69-77. 2000....
- Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trialLeo R Zacharski
White River Junction VA Medical Center, Research Service, Department of Veterans Affairs Medical Center, White River Junction, VT 05001, USA
JAMA 297:603-10. 2007..Accumulation of iron in excess of physiologic requirements has been implicated in risk of cardiovascular disease because of increased iron-catalyzed free radical-mediated oxidative stress...
- Treatment of malignancy by activation of the plasminogen systemLeo R Zacharski
VA Medical and Regional Office Center, White River Junction, Vermont 05009, USA
Semin Thromb Hemost 28:5-18. 2002..These observations suggest novel approaches to the experimental therapy of cancer...
- Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trialLeo R Zacharski
Research Service 151, White River Junction VA Medical Center, Department of Veterans Affairs Medical Center, 215 North Hartland Road, White River Junction, VT 05009, USA
J Natl Cancer Inst 100:996-1002. 2008..Excess iron has been implicated in cancer risk through increased iron-catalyzed free radical-mediated oxidative stress...
- Remission of paroxysmal atrial fibrillation with iron reduction in haemophilia AL R Zacharski
Section of Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
Haemophilia 16:726-30. 2010....
- Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial diseaseLeo R Zacharski
Department of Veterans Affairs Medical Center, White River Jct, VT 05009, USA
Am Heart J 162:949-957.e1. 2011..The mechanism of the age-specific effect was explored...
- The coagulation system as a target for experimental therapy of human gliomasJ T Loynes
Section of Hematology Oncology, DartmouthHitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03257, USA
Expert Opin Ther Targets 7:399-404. 2003..This approach offers the prospect of a novel treatment for this devastating tumour type that does not share the toxicities of conventional cancer therapies...
- Low-molecular-weight heparin in oncologyLeo R Zacharski
VA Medical and Regional Office Center, Vermont, USA
Anticancer Res 23:2789-93. 2003..Outstanding issues relating to thromboprophylaxis and treatment of VTE in patients with cancer and the clinical trials that may resolve these issues are also highlighted...
- Getting the iron out: phlebotomy for Alzheimer's disease?Barney E Dwyer
Research Service, Department of Veterans Affairs Medical Center, White River Junction, VT 05009 0001, United States
Med Hypotheses 72:504-9. 2009..Testing this hypothesis could provide valuable insight into the causation of AD and suggest novel preventive and treatment strategies...
- Low molecular weight heparins as extended prophylaxis against recurrent thrombosis in cancer patientsCocav A Engman
Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
J Natl Compr Canc Netw 6:637-45. 2008..Further clinical research is needed to evaluate the potential survival benefits of LMWH therapy in patients with cancer...
- Coagulation biology in glioma pathogenesis: a missing link?C E Fadul
Section of Hematology Oncology, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH and VA Hospital, White River Jct, VT, USA
J Thromb Haemost 3:1915-6. 2005
- Successful donation and transplantation of multiple organs after fatal poisoning with brodifacoum, a long-acting anticoagulant rodenticide: case reportD L Ornstein
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
Transplantation 67:475-8. 1999..In this report, we describe a case of multiple organ donation from a previously healthy individual who died from poisoning with the long-acting anticoagulant rodenticide, brodifacoum...
- Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer?L R Zacharski
Department of Veterans Affairs Medical Center, White River Junction, VT 05009, USA
J Thromb Haemost 3:424-7. 2005
- Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancerLeo R Zacharski
Veterans Administration Medical Center, White River Junction, Vermont 05001, USA
Semin Thromb Hemost 29:239-46. 2003..Although limited experience to date in human disease has supported these concepts, resolution of cause-and-effect relationships will require performance of additional rationally designed clinical trials...
- The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular diseaseD J Solet
Section of Cardiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
Am J Med 111:45-53. 2001..ADP inhibitors, by blocking an alternate pathway of platelet activation, are slightly more effective than aspirin in reducing cardiovascular events...
- Interfering with hemostatic system components: possible new approaches to antiangiogenic therapyMarek Z Wojtukiewicz
Department of Oncology, Medical University, Bialystok, Poland
Semin Thromb Hemost 30:145-56. 2004..Rather it is aimed at restoring the normal state by modulating the dysregulated interaction of tumor cells with their environment that is characteristic of cancer...
- Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidenceRichard H Cosgrove
Department of Pharmacy, Harper University Hospital, Detroit Medical Center, Detroit, Michigan 48201, USA
Semin Thromb Hemost 28:79-87. 2002..Proposals for the most likely targets of the effective heparins include enzyme interaction, cellular growth modifications, and antiangiogenesis...
- Activity of heparins in experimental models of malignancy: Possible explanations for anticancer effects in humansDeborah L Ornstein
59th MDW MMIH, Wilford Hall Medical Center, 2200 Bergquist Drive, Lackland Air Force Base, San Antonio, TX 78236, USA
Clin Hemorheol Microcirc 26:33-40. 2002....
- A rebuttal: vitamin K antagonists and cancer survivalLeo R Zacharski
Thromb Haemost 88:173-4; author reply 175. 2002
- Cancer and venous thromboembolism: a multidisciplinary approachHenrik T Sørensen
Department of Clinical Epidemiology, Aarhus and Aalborg University Hospitals, Denmark
Clin Lab 49:615-23. 2003..However, the clinical implications of these findings must await properly designed and conducted randomized clinical trials...
- Heparin as an anticancer therapeuticLeo R Zacharski
Hamilton Health Sciences Henderson Hospital, 711 Concession Street, Hamilton, ON L8V1C3, Canada
Expert Opin Investig Drugs 17:1029-37. 2008....
- Cytokine signatures in atherosclerotic claudicantsRalph G DePalma
Veterans Affairs Central Office, 20420, Washington, DC 20040, USA
J Surg Res 111:215-21. 2003..Iron accumulation and inflammation may affect atherosclerosis. This study intended to define a cytokine signature in atherosclerotic claudicants and to determine whether reduction in serum ferritin by phlebotomy influenced this pattern...
- Occurrence of components of fibrinolytic pathways in situ in laryngeal cancerMarek Z Wojtukiewicz
Department of Oncology, Medical Academy, Bialystok, Poland
Semin Thromb Hemost 29:317-20. 2003..Trace staining was found for u-PA receptor (u-PAR) in differentiated tumor cells. The significance of coagulation and fibrinolytic pathways present in situ to the economy of laryngeal carcinoma remains to be determined...
- Statins and biomarkers in claudicants with peripheral arterial disease: cross-sectional studyRalph G DePalma
Department of Veterans Affairs, Washington, DC 20420, USA
Vascular 14:193-200. 2006..Unexpectedly, serum inflammatory cytokine IL-6 levels were significantly higher in PAD subjects receiving statins. There was no difference in measured inflammatory markers in PAD subjects with concomitant CAD...
- Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomesDuk Hee Lee
Division of Preventive Medicine, School of Medicine, Kyungpook National University, Jung Gu, Daegu, South Korea
Am Heart J 151:1247.e1-7. 2006....
- Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancerMarek Z Wojtukiewicz
Department of Oncology, Medical Academy, Bialystok, Poland
Semin Thromb Hemost 29:291-300. 2003..Colocalization of VEGF with hemostatic proteins suggests that they may cooperate in the pathogenesis of gastric cancer...
- Evaluating the role of serine protease inhibition in the management of tumor micrometastasesJoe B Putnam
University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
Oncology (Williston Park) 17:9-30; quiz 31-2. 2003
- The functions of plasminogen activator inhibitor-1: do we have all the pieces of PAI?Mary Jo Mulligan-Kehoe
Thromb Res 117:483-6. 2006
- The coagulation system as a target for the treatment of human gliomasDeborah L Ornstein
Special Hematology and Coagulation Laboratory, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas 78236, USA
Semin Thromb Hemost 28:19-28. 2002..This article reviews the implications of coagulation activation in human gliomas and provides a rationale for clinical testing of anticoagulants as part of a treatment strategy for this devastating human cancer...
- Heparin treatment of malignancy: the case for clinical trials in colon cancerLeo R Zacharski
Thromb Res 110:213-4. 2003
- Regression of metastatic non-small cell lung cancer with low molecular weight heparinJames T Loynes
Thromb Haemost 88:686. 2002
- Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cellsDeborah L Ornstein
Department of Laboratory Medicine, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
Nutr Cancer 58:115-26. 2007..Our data indicate that one mechanism by which iron may stimulate uPA production is through the generation of intracellular ROI and activation of NF-kappaB-mediated signaling pathways...
- Bloodletting: past and presentRalph G DePalma
Patient Care Services VA Central Office, Washington, DC, USA
J Am Coll Surg 205:132-44. 2007